Gedeon Richter Plc. Announces Positive Phase IIIb Top-line Results of Cariprazine for the Treatment of Patients with Predominant Negative Symptoms of Schizophrenia

Gedeon Richter Plc. today announced positive top-line results from a Phase IIIb trial evaluating the efficacy, safety and tolerability of cariprazine, a new atypical antipsychotic, in adult schizophrenia patients with persistent and predominant negative symptoms.